黄芪颗粒联合厄贝沙坦治疗高血压早期肾损害的疗效观察

目的观察黄芪颗粒联合厄贝沙坦治疗高血压早期。肾损害的临床疗效。方法将70例高血压肾病患者随机分为对照组（35例）和观察组（35例），对照组加用厄贝沙坦150mg，1次／日。治疗组除加用厄贝沙坦150mg，1次／日外，另加用黄芪颗粒4g，2次／日治疗。疗程3个月，治疗前及治疗后1月、3月复查以下各项指标：血压、血常规、电解质、肝功能、血清肌酐、血尿素氮、尿酸、24h尿蛋白定量、血、尿β2微球蛋白。结果和治疗前比较，治疗1月和3月后，对照组和观察组血、尿Bz微球蛋白、收缩压、舒张压、尿酸及24h尿蛋白定量均显著下降（P〈0．01）。和对照组比较，观察组治疗1月后，24h尿蛋白定量和血、尿β2微球蛋白水平均明显下降（P〈0．05）。治疗3月后，24h尿蛋白定量、肌酐、尿酸明显下降（P〈0．05），血、尿β2微球蛋白水平均显著下降（P〈0．01）.结论黄芪颗粒联合厄贝沙坦治疗高血压早期肾损害可有效降低尿蛋白、改善肾功能。

The efficacy of astragali granules combined with irbesartan for early renal injury induced by hypertension

Objective To observe the clinical efficacy of astragali granules combined with irbesartan in the treatment of early renal injury induced by hypertension. Methods 70 patients with hypertensive nephropathy were randomly assigned to receive irbesartan of 150 mg alone once daily （ 75 patients, control group ）, or irbesartan of 150 mg once daily plus astragali granules of 4 g twice daily （ 75 patients, 75 patients, study group ） for three months. Levels of urinary β2MG, serum β2MG, 24-hour urinary protein were detected, and related clinical indicators were observed before and 1 and 3 months after treatment. Results As compared with the baselines, levels of urinary β2MG, serum β2MG, 2g-hour urinary protein, and uric acid were decreased significantly one month after treatment in the control group （ P〈 0.05 ） and study group （ P 〈 0.01 ）, and were remarkably declined three months after treatment in both groups （ P 〈 0.01 ）. As compared with the control group, levels of urinary ~2MG, serum β2MG, and 24-hour urinary protein were decreased significantly one month after treatment in study group （ P 〈 0. 05 ）; levels of 24-hour urinary protein, creatinine, and uric acid were decreased significantly three months after treatment in the study group （ P 〈 0.05 ） and levels of urinary and serum β2MG were remarkably decreased （ P 〈 0.01 ）. Conclusions Astragali granules combined with irbesartan for early renal injury induced by hypertension.is more effective in reducing urinary protein and improving renal function.